• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Structural basis for specific ligation of the peroxisome proliferator-activated receptor δ.过氧化物酶体增殖物激活受体 δ 的特异性连接的结构基础。
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):E2563-E2570. doi: 10.1073/pnas.1621513114. Epub 2017 Mar 20.
2
Crystal structures of the ligand-binding domain of human peroxisome proliferator-activated receptor δ in complexes with phenylpropanoic acid derivatives and a pyridine carboxylic acid derivative.人过氧化物酶体增殖物激活受体 δ 配体结合域与苯丙酸衍生物和吡啶羧酸衍生物复合物的晶体结构。
Acta Crystallogr F Struct Biol Commun. 2022 Feb 1;78(Pt 2):81-87. doi: 10.1107/S2053230X22000449. Epub 2022 Jan 31.
3
Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.人源过氧化物酶体增殖物激活受体 δ(PPAR-δ)选择性配体结合的结构见解。
PLoS One. 2012;7(5):e33643. doi: 10.1371/journal.pone.0033643. Epub 2012 May 11.
4
Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.作为一种 PPARα/γ双重激动剂,用于治疗非酒精性脂肪性肝病和糖尿病血脂异常的药物沙格列汀的结构基础。
Biol Pharm Bull. 2021;44(9):1210-1219. doi: 10.1248/bpb.b21-00232.
5
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.贝扎贝特、非诺贝特和帕玛贝特对人 PPARα/δ/γ 亚型选择性的功能和结构见解。
Int J Mol Sci. 2022 Apr 25;23(9):4726. doi: 10.3390/ijms23094726.
6
Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.具有非典型结合模式的磺酰基噻二唑类化合物作为部分双重过氧化物酶体增殖物激活受体 (PPAR)γ/δ 激动剂,具有高效力和体内疗效。
ChemMedChem. 2011 Apr 4;6(4):633-53. doi: 10.1002/cmdc.201100047. Epub 2011 Mar 11.
7
[PPARα-Ligand Binding Modes Revealed by X-ray Crystallography].[X射线晶体学揭示的PPARα配体结合模式]
Yakugaku Zasshi. 2021;141(11):1267-1274. doi: 10.1248/yakushi.21-00138.
8
X-ray crystal structure of rivoglitazone bound to PPARγ and PPAR subtype selectivity of TZDs.罗格列酮与 PPARγ 的 X 射线晶体结构及 TZDs 的 PPAR 亚型选择性。
Biochim Biophys Acta Gen Subj. 2017 Aug;1861(8):1981-1991. doi: 10.1016/j.bbagen.2017.05.008. Epub 2017 May 9.
9
Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.通过与内源性脂肪酸的共价修饰对过氧化物酶体增殖物激活受体γ(PPARγ)激活的结构洞察。
J Mol Biol. 2009 Jan 9;385(1):188-99. doi: 10.1016/j.jmb.2008.10.039. Epub 2008 Oct 19.
10
Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects.新型过氧化物酶体增殖物激活受体(PPAR)γ和PPARδ配体产生不同的生物学效应。
J Biol Chem. 1999 Mar 5;274(10):6718-25. doi: 10.1074/jbc.274.10.6718.

引用本文的文献

1
Highlights on U.S. FDA-approved halogen-containing drugs in 2024.2024年美国食品药品监督管理局批准的含卤素药物亮点。
Eur J Med Chem. 2025 Apr 5;287:117380. doi: 10.1016/j.ejmech.2025.117380. Epub 2025 Feb 9.
2
Peroxisome proliferator-activated receptor delta and liver diseases.过氧化物酶体增殖物激活受体δ与肝脏疾病
Hepatol Commun. 2025 Feb 3;9(2). doi: 10.1097/HC9.0000000000000646. eCollection 2025 Feb 1.
3
Molecular pathways involved in the control of contractile and metabolic properties of skeletal muscle fibers as potential therapeutic targets for Duchenne muscular dystrophy.参与控制骨骼肌纤维收缩和代谢特性的分子途径作为杜氏肌营养不良症的潜在治疗靶点。
Front Physiol. 2024 Dec 9;15:1496870. doi: 10.3389/fphys.2024.1496870. eCollection 2024.
4
Highly potent and selective PPARδ agonist reverses memory deficits in mouse models of Alzheimer's disease.高活性和选择性的过氧化物酶体增殖物激活受体 δ 激动剂可逆转阿尔茨海默病小鼠模型的记忆缺陷。
Theranostics. 2024 Sep 16;14(16):6088-6108. doi: 10.7150/thno.96707. eCollection 2024.
5
Automated design of multi-target ligands by generative deep learning.基于生成式深度学习的多靶标配体自动化设计。
Nat Commun. 2024 Sep 11;15(1):7946. doi: 10.1038/s41467-024-52060-8.
6
Functional and Structural Insights into the Human PPARα/δ/γ Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor.抗非酒精性脂肪性肝炎(NASH)研究药物拉尼贝特、塞拉地帕和依拉贝特对人过氧化物酶体增殖物激活受体α/δ/γ靶向偏好的功能和结构见解
Antioxidants (Basel). 2023 Jul 29;12(8):1523. doi: 10.3390/antiox12081523.
7
Ligand dependent interaction between PC-TP and PPARδ mitigates diet-induced hepatic steatosis in male mice.配体依赖性相互作用 PC-TP 和 PPARδ 减轻雄性小鼠饮食诱导的肝脂肪变性。
Nat Commun. 2023 May 12;14(1):2748. doi: 10.1038/s41467-023-38010-w.
8
Peptide Helix-Y as Potential Effector for Peroxisome Proliferator-Activated Receptors.肽螺旋-Y作为过氧化物酶体增殖物激活受体的潜在效应物
PPAR Res. 2023 Apr 15;2023:8047378. doi: 10.1155/2023/8047378. eCollection 2023.
9
Deciphering the relational dynamics of AF-2 domain of PAN PPAR through drug repurposing and comparative simulations.通过药物再利用和比较模拟来破译 PAN PPAR 的 AF-2 结构域的关系动力学。
PLoS One. 2023 Mar 31;18(3):e0283743. doi: 10.1371/journal.pone.0283743. eCollection 2023.
10
A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice.一种三联法尼醇X受体和过氧化物酶体增殖物激活受体α/δ激活剂可逆转饮食诱导的小鼠非酒精性脂肪性肝炎中的肝纤维化。
Commun Chem. 2020 Nov 13;3(1):174. doi: 10.1038/s42004-020-00411-z.

本文引用的文献

1
A structural perspective on nuclear receptors as targets of environmental compounds.从结构角度看核受体作为环境化合物的靶点
Acta Pharmacol Sin. 2015 Jan;36(1):88-101. doi: 10.1038/aps.2014.133. Epub 2014 Dec 15.
2
Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.过氧化物酶体增殖物激活受体靶点治疗代谢性疾病。
Mediators Inflamm. 2013;2013:549627. doi: 10.1155/2013/549627. Epub 2013 May 27.
3
PPARγ signaling and metabolism: the good, the bad and the future.过氧化物酶体增殖物激活受体 γ 信号转导与代谢:好、坏与未来。
Nat Med. 2013 May;19(5):557-66. doi: 10.1038/nm.3159. Epub 2013 May 7.
4
Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ.SIRT1 通过去乙酰化 Pparγ 介导白色脂肪组织的棕色样重塑。
Cell. 2012 Aug 3;150(3):620-32. doi: 10.1016/j.cell.2012.06.027.
5
Evolution of the chalcone-isomerase fold from fatty-acid binding to stereospecific catalysis.查尔酮异构酶折叠从脂肪酸结合到立体特异性催化的演变。
Nature. 2012 May 13;485(7399):530-3. doi: 10.1038/nature11009.
6
Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.人源过氧化物酶体增殖物激活受体 δ(PPAR-δ)选择性配体结合的结构见解。
PLoS One. 2012;7(5):e33643. doi: 10.1371/journal.pone.0033643. Epub 2012 May 11.
7
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.过氧化物酶体增殖物激活受体在癌症发生和化学预防中的作用。
Nat Rev Cancer. 2012 Feb 9;12(3):181-95. doi: 10.1038/nrc3214.
8
PPARs: fatty acid sensors controlling metabolism.过氧化物酶体增殖物激活受体(PPARs):脂肪酸感应器调控代谢。
Semin Cell Dev Biol. 2012 Aug;23(6):631-9. doi: 10.1016/j.semcdb.2012.01.003. Epub 2012 Jan 18.
9
The nuclear receptor PPARβ/δ programs muscle glucose metabolism in cooperation with AMPK and MEF2.核受体 PPARβ/δ 与 AMPK 和 MEF2 合作调控肌肉葡萄糖代谢。
Genes Dev. 2011 Dec 15;25(24):2619-30. doi: 10.1101/gad.178434.111. Epub 2011 Dec 1.
10
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.一种非激动剂 PPARγ 配体通过阻断 Cdk5 介导的磷酸化发挥抗糖尿病作用。
Nature. 2011 Sep 4;477(7365):477-81. doi: 10.1038/nature10383.

过氧化物酶体增殖物激活受体 δ 的特异性连接的结构基础。

Structural basis for specific ligation of the peroxisome proliferator-activated receptor δ.

机构信息

Howard Hughes Medical Institute, The Salk Institute for Biological Studies, La Jolla, CA 92037.

Jack H. Skirball Center for Chemical Biology and Proteomics, The Salk Institute for Biological Studies, La Jolla, CA 92037.

出版信息

Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):E2563-E2570. doi: 10.1073/pnas.1621513114. Epub 2017 Mar 20.

DOI:10.1073/pnas.1621513114
PMID:28320959
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5380080/
Abstract

The peroxisome proliferator-activated receptor (PPAR) family comprises three subtypes: PPARα, PPARγ, and PPARδ. PPARδ transcriptionally modulates lipid metabolism and the control of energy homeostasis; therefore, PPARδ agonists are promising agents for treating a variety of metabolic disorders. In the present study, we develop a panel of rationally designed PPARδ agonists. The modular motif affords efficient syntheses using building blocks optimized for interactions with subtype-specific residues in the PPARδ ligand-binding domain (LBD). A combination of atomic-resolution protein X-ray crystallographic structures, ligand-dependent LBD stabilization assays, and cell-based transactivation measurements delineate structure-activity relationships (SARs) for PPARδ-selective targeting and structural modulation. We identify key ligand-induced conformational transitions of a conserved tryptophan side chain in the LBD that trigger reorganization of the H2'-H3 surface segment of PPARδ. The subtype-specific conservation of H2'-H3 sequences suggests that this architectural remodeling constitutes a previously unrecognized conformational switch accompanying ligand-dependent PPARδ transcriptional regulation.

摘要

过氧化物酶体增殖物激活受体 (PPAR) 家族包括三种亚型:PPARα、PPARγ 和 PPARδ。PPARδ 转录调节脂质代谢和能量稳态的控制;因此,PPARδ 激动剂是治疗多种代谢紊乱的有前途的药物。在本研究中,我们开发了一组合理设计的 PPARδ 激动剂。模块化基序可使用针对 PPARδ 配体结合域 (LBD) 中特定于亚型的残基相互作用进行优化的构建块进行高效合成。原子分辨率的蛋白质 X 射线晶体结构、配体依赖性 LBD 稳定测定和基于细胞的转激活测量相结合,描绘了 PPARδ 选择性靶向和结构调节的构效关系 (SAR)。我们确定了 LBD 中保守色氨酸侧链的关键配体诱导构象转变,该转变触发 PPARδ 的 H2'-H3 表面片段的重组。H2'-H3 序列的亚型特异性保守性表明,这种结构重塑构成了伴随配体依赖性 PPARδ 转录调节的以前未被识别的构象开关。